Fabrice Schneider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fabrice Schneider has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Baptiste Ricco
Research and Anatomy Laboratory, University of Poitiers, Poitiers, France; Department of Vascular Surgery, University Hospital of Rangueil, Toulouse, France
4 shared publications - Giulio Illuminati
Department of Surgery, Sapienza University of Rome, Viale Regina Elena, 324, 00161 Rome, Italy
3 shared publications Federica Masci
The Department of Surgical Sciences, University of Rome "La Sapienza", Rome, Italy
2 shared publications- Samy Hadjadj
L'Institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU NANTES, Nantes, France
2 shared publications - Anaïs Peran Dubourg
Department of Vascular Surgery, University Hospital of Poitiers, Poitiers, France
1 shared publication - Elise Gand
CHU Poitiers Clinical Investigation Center CIC 1402, INSERM, University of Poitiers, 86000 Poitiers, France
1 shared publication
Latest Publications
- 1 November 2018
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 53, 3
Clinical Risk Factors and Biomarkers Approach to Predict the Level of Amputation in Type 2 Diabetic Patients
- 1 November 2018
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 53, 3
Clinical Risk Factors and Biomarkers Approach to Predict the Level of Amputation in Type 2 Diabetic Patients
- Open Access
- 8 June 2018
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 17 (1) , 1-12
Influence of micro- and macro-vascular disease and Tumor Necrosis Factor Receptor 1 on the level of lower-extremity amputation in patients with type 2 diabetes
Patients with type 2 diabetes (T2D) face a high amputation rate. We investigated the relationship between the level of amputation and the presence of micro or macro-vascular disease and related circulating biomarkers, Tumor Necrosis Factor Receptor 1 (TNFR1) and Angiopoietin like-2 protein (ANGPTL2). We have analyzed data from 1468 T2D participants in a single center prospective cohort (the SURDIAGENE cohort). Our outcome was the occurrence of lower limb amputation categorized in minor (below-ankle) or major (above ankle) amputation. Microvascular disease was defined as a history of albuminuria [microalbuminuria: uACR (urinary albumine-to-creatinine ratio) 30–299 mg/g or macroalbuminuria: uACR ≥ 300 mg/g] and/or severe diabetic retinopathy or macular edema. Macrovascular disease at baseline was divided into peripheral arterial disease (PAD): peripheral artery revascularization and/or major amputation and in non-peripheral macrovascular disease: coronary artery revascularization, myocardial infarction, carotid artery revascularization, stroke. We used a proportional hazard model considering survival without minor or major amputation. During a median follow-up period of 7 (0.5) years, 79 patients (5.5%) underwent amputation including 29 minor and 50 major amputations. History of PAD (HR 4.37 95% CI [2.11–9.07]; p < 0.001), severe diabetic retinopathy (2.69 [1.31–5.57]; p = 0.0073), male gender (10.12 [2.41–42.56]; p = 0.0016) and serum ANGPTL2 concentrations (1.25 [1.08–1.45]; p = 0.0025) were associated with minor amputation outcome. History of PAD (6.91 [3.75–12.72]; p < 0.0001), systolic blood pressure (1.02 [1.00–1.03]; p = 0.004), male gender (3.81 [1.67–8.71]; p = 0.002), and serum TNFR1 concentrations (HR 13.68 [5.57–33.59]; p < 0.0001) were associated with major amputation outcome. Urinary albumin excretion was not significantly associated with the risk of minor and major amputation. This study suggests that the risk factors associated with the minor vs. major amputation including biomarkers such as TNFR1 should be considered differently in patients with T2D.
- 8 June 2018
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 17 (1) , 1-12
Open AccessInfluence of micro- and macro-vascular disease and Tumor Necrosis Factor Receptor 1 on the level of lower-extremity amputation in patients with type 2 diabetes
Patients with type 2 diabetes (T2D) face a high amputation rate. We investigated the relationship between the level of amputation and the presence of micro or macro-vascular disease and related circulating biomarkers, Tumor Necrosis Factor Receptor 1 (TNFR1) and Angiopoietin like-2 protein (ANGPTL2). We have analyzed data from 1468 T2D participants in a single center prospective cohort (the SURDIAGENE cohort). Our outcome was the occurrence of lower limb amputation categorized in minor (below-ankle) or major (above ankle) amputation. Microvascular disease was defined as a history of albuminuria [microalbuminuria: uACR (urinary albumine-to-creatinine ratio) 30–299 mg/g or macroalbuminuria: uACR ≥ 300 mg/g] and/or severe diabetic retinopathy or macular edema. Macrovascular disease at baseline was divided into peripheral arterial disease (PAD): peripheral artery revascularization and/or major amputation and in non-peripheral macrovascular disease: coronary artery revascularization, myocardial infarction, carotid artery revascularization, stroke. We used a proportional hazard model considering survival without minor or major amputation. During a median follow-up period of 7 (0.5) years, 79 patients (5.5%) underwent amputation including 29 minor and 50 major amputations. History of PAD (HR 4.37 95% CI [2.11–9.07]; p < 0.001), severe diabetic retinopathy (2.69 [1.31–5.57]; p = 0.0073), male gender (10.12 [2.41–42.56]; p = 0.0016) and serum ANGPTL2 concentrations (1.25 [1.08–1.45]; p = 0.0025) were associated with minor amputation outcome. History of PAD (6.91 [3.75–12.72]; p < 0.0001), systolic blood pressure (1.02 [1.00–1.03]; p = 0.004), male gender (3.81 [1.67–8.71]; p = 0.002), and serum TNFR1 concentrations (HR 13.68 [5.57–33.59]; p < 0.0001) were associated with major amputation outcome. Urinary albumin excretion was not significantly associated with the risk of minor and major amputation. This study suggests that the risk factors associated with the minor vs. major amputation including biomarkers such as TNFR1 should be considered differently in patients with T2D.
- Open Access
- 1 January 2018
- Published by Elsevier in EJVES Short Reports
- Vol. 39, 50-53
Use of VIABAHN Open Revascularisation TEChnique (VORTEC) for Iliofemoral Bypass
- 1 January 2018
- Published by Elsevier in EJVES Short Reports
- Vol. 39, 50-53
Open AccessUse of VIABAHN Open Revascularisation TEChnique (VORTEC) for Iliofemoral Bypass
- 1 April 2017
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 40, 39-43
Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study
- 1 April 2017
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 40, 39-43
Dual Antiplatelet Therapy Does Not Increase the Risk of Bleeding After Carotid Endarterectomy: Results of a Prospective Study
- 1 December 2013
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 58 (6) , 1709-1715
Debate: Whether young, good-risk patients should be treated with endovascular abdominal aortic aneurysm repair
- 1 December 2013
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 58 (6) , 1709-1715
Debate: Whether young, good-risk patients should be treated with endovascular abdominal aortic aneurysm repair
- 1 May 2013
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 45 (5) , 416-419
Part One: For the Motion. Completion Angiography Should be Used Routinely Following Carotid Endarterectomy
- 1 May 2013
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 45 (5) , 416-419
Part One: For the Motion. Completion Angiography Should be Used Routinely Following Carotid Endarterectomy